Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.
Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before
Here’s Why Eli Lilly (LLY) Traded Down in Q4
Fred Alger Management, an investment management company, released its “Alger Spectra Fund” fourth quarter 2024 investor letter. A copy of the investor letter can be downloaded here. U.S.
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
Eli Lilly reports mixed earnings, increases 2025 guidance
Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 billion.
Eli Lilly reports Q4 EPS $5.32, consensus $5.08
Reports Q4 revenue $13.53B, consensus $13.43B. “2024 was a highly successful year for Lilly,” said David Ricks, Lilly’s chair and CEO. “We had
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar,
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
MM&M2d
Inside Eli Lilly’s bold breast cancer awareness ad debut at the Grammys
Eli Lilly’s latest TV ad, unveiled during the Grammys on Sunday night, highlights the importance of early diagnosis for ...
BioSpace14h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
STAT12h
Lilly expands GLP-1 research to hypertension, neuro conditions
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
FierceBiotech1d
Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...